A major clinical setback has sent Ultragenyx Pharmaceutical’s stock to a fresh annual low. The catalyst was the failure of its key drug candidate, setrusumab, to meet primary endpoints in a pivotal Phase 3 trial for Osteogenesis imperfecta, commonly known as brittle bone disease. In response, analysts at Goldman Sachs have taken decisive action, downgrading the stock and slashing their price target.
Goldman Sachs Revises Outlook
The investment bank shifted its rating on Ultragenyx from “Buy” to “Neutral.” Its new price target was set at a mere $25 per share, a significant reduction. This reassessment stems directly from the setrusumab trial results, which have removed a fundamental pillar of the company’s previous valuation.
Interestingly, the broader analyst community presents a contrasting view. The current consensus rating remains at “Moderate Buy,” based on data showing 15 “Buy” recommendations against just two “Hold” and one “Sell” ratings. However, the average price target among analysts sits at $60.47, revealing a substantial gap between majority expectations and the current market reality, with the stock trading at a 52-week low.
Pipeline Shifts Focus to GTX-102
With the disappointment surrounding setrusumab, investor attention is now firmly fixed on GTX-102. This investigational therapy for Angelman syndrome is viewed as the company’s most important value driver moving forward. The market is eagerly awaiting data from its Phase 3 study, expected to be released sometime in 2026.
Should investors sell immediately? Or is it worth buying Ultragenyx Pharmaceutical?
The long-term investment thesis also hinges on progress with two gene therapies, DTX401 and UX111. Critical regulatory milestones for these candidates are anticipated in the second half of 2026, which could determine the future success of Ultragenyx’s development pipeline.
Financial Path and Personnel Moves
Beyond clinical developments, the company’s financial trajectory remains a key consideration for investors. Management has targeted achieving GAAP profitability for the full calendar year 2026. In a separate corporate development, Ultragenyx recently granted approximately 10,800 stock options to two new employees as an incentive. These options will vest over a four-year period.
The investment narrative for Ultragenyx has now completely shifted to the upcoming GTX-102 data. Positive results from this trial could lay the groundwork for a fundamental re-rating of the stock. Until then, however, the equity is likely to remain sensitive to the uncertainty created by the setrusumab trial failure.
Ad
Ultragenyx Pharmaceutical Stock: Buy or Sell?! New Ultragenyx Pharmaceutical Analysis from March 25 delivers the answer:
The latest Ultragenyx Pharmaceutical figures speak for themselves: Urgent action needed for Ultragenyx Pharmaceutical investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.
Ultragenyx Pharmaceutical: Buy or sell? Read more here...
